拓新药业(301089) - 2025 Q2 - 季度财报

Important Notes, Table of Contents, and Definitions This section covers essential disclaimers, the report's structure, and definitions of key terms for clarity Important Notes The board, supervisory board, and senior management guarantee the report's accuracy, with financial reports affirmed by key personnel, and no dividend distribution planned - The company's board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report, free from false records, misleading statements, or major omissions, and assume individual and joint legal responsibility[5] - Company head Yang Xining, chief financial officer Jiao Huijuan, and head of accounting department Yu Zhenwei declare that the financial report in this semi-annual report is true, accurate, and complete[5] - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital[6] Table of Contents This section lists the report's eight main chapters, covering important notes, company profile, management discussion and analysis, corporate governance, significant matters, share changes, bond information, and financial reports, along with their starting page numbers - The report contains eight main chapters, covering comprehensive information on company operations, finance, governance, and significant matters[8] Reference Documents Reference documents include financial statements signed by the company head and chief accountant, the original semi-annual report signed by the legal representative, and all publicly disclosed company documents and announcements from the reporting period - Reference documents include financial statements signed and sealed by the company head, chief financial officer, and head of accounting department[10] - Reference documents include the original text of the 2025 semi-annual report signed by the company's legal representative[11] - Reference documents include the originals of all company documents and announcements publicly disclosed on the CSRC-designated website during the reporting period[12] Definitions This section defines common terms used in the report, including company names, subsidiaries, relevant organizations, industry terms (e.g., API, GMP, DMF), and legal regulations, ensuring accurate understanding of the report content - "Tuoxin Pharmaceutical, the Company, the Shareholding Company" refers to Tuoxin Pharmaceutical Group Co., Ltd. and Xinxiang Tuoxin Pharmaceutical Co., Ltd[15] - "Active Pharmaceutical Ingredients (API)" refers to the active pharmaceutical ingredients, which are the basic substances constituting the pharmacological action of drugs[15] - "GMP" refers to Good Manufacturing Practice, which sets clear requirements for raw materials, facilities, equipment, hygiene, personnel training, and quality management required for drug production[15] Company Profile and Key Financial Indicators This section provides an overview of the company's basic information, contact details, and key financial performance metrics for the reporting period Company Profile Tuoxin Pharmaceutical Group Co., Ltd., stock abbreviation "Tuoxin Pharmaceutical", stock code 301089, is listed on the Shenzhen Stock Exchange, with Yang Xining as its legal representative - Company stock abbreviation: Tuoxin Pharmaceutical, stock code: 301089[17] - Company stock listed on: Shenzhen Stock Exchange[17] - Company legal representative: Yang Xining[17] Contacts and Contact Information The company's board secretary is Yang Yuhua, and the securities affairs representative is Li Haijing; their contact address is 515 Kelong Avenue, High-tech Zone, Xinxiang City, Henan Province, with phone/fax 0373-6351918 and email tuoxinyyh@163.com - Board Secretary: Yang Yuhua; Securities Affairs Representative: Li Haijing[18] - Contact address: 515 Kelong Avenue, High-tech Zone, Xinxiang City, Henan Province[18] - Phone/Fax: 0373-6351918; Email: tuoxinyyh@163.com[18] Other Information During the reporting period, there were no changes in the company's registered address, office address, website, email, information disclosure and filing locations, or registration status; refer to the 2024 annual report for details - The company's registered address, office address and postal code, website, email, etc., remained unchanged during the reporting period; refer to the 2024 annual report for details[19] - Information disclosure and filing locations remained unchanged during the reporting period; refer to the 2024 annual report for details[20] - The company's registration status remained unchanged during the reporting period; refer to the 2024 annual report for details[21] Key Accounting Data and Financial Indicators In the first half of 2025, the company's operating revenue decreased by 16.85% year-on-year, net profit attributable to shareholders plummeted by 927.39% to -18.28 million yuan, operating cash flow turned negative, and total assets and net assets attributable to shareholders both declined 2025 Semi-Annual Key Accounting Data and Financial Indicators | Indicator | Current Period (yuan) | Prior Period (yuan) | Current Period vs. Prior Period Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 181,899,752.24 | 218,756,705.10 | -16.85% | | Net Profit Attributable to Shareholders of Listed Company | -18,280,549.55 | -1,779,323.09 | -927.39% | | Net Profit Attributable to Shareholders of Listed Company After Deducting Non-Recurring Gains and Losses | -22,207,618.53 | -7,967,008.09 | -178.74% | | Net Cash Flow from Operating Activities | -23,014,635.10 | 59,959,775.55 | -138.38% | | Basic Earnings Per Share (yuan/share) | -0.14 | -0.01 | -1,300.00% | | Diluted Earnings Per Share (yuan/share) | -0.14 | -0.01 | -1,300.00% | | Weighted Average Return on Net Assets | -1.18% | -0.11% | -1.07% | | Period-End | Prior Year-End | Period-End vs. Prior Year-End Change | | Total Assets | 1,707,229,980.16 | 1,758,243,932.05 | -2.90% | | Net Assets Attributable to Shareholders of Listed Company | 1,534,239,510.89 | 1,552,520,060.44 | -1.18% | [Differences in Accounting Data under Domestic and Overseas Accounting Standards](index=7&type=section&id=%E4%BA%94%E3%80%81%E5%A2%83%E5%86%85%E5%A